Journal of Cutaneous Medicine and Surgery

, Volume 8, Issue 4, pp 205–212 | Cite as

Understanding the New Clinical Landscape for Psoriasis: A Comparative Review of Biologics

Basic/Clinical Science



Encouraging results from clinical trials suggest that biologic therapies are effective treatments for psoriasis.


The aim of our study was to evaluate the scientific evidence for the efficacy and safety of biologic drugs for psoriasis.


The studies reviewed include data on the biologies alefacept, efalizumab, etanercept, and infliximab. This article reviews all data published in the dermatology literature listed in the MEDLINE database, as well as data presented as abstracts and posters at dermatology society meetings, including the annual meetings of the American Academy of Dermatology.


The majority of the studies used an improvement from baseline of 75% or more in the psoriasis area and severity index (PASI 75) as the primary measure of efficacy.


Overall, biologics represent an important addition to the psoriatic therapies and have a great impact on the disease course and life quality of those afflicted with psoriasis.



Des résultats encourageants d’essais cliniques indiquent que les biothérapies sont efficaces dans le traitement du psoriasis.


Évaluer les preuves scientifiques montant l’innocuité et l’efficacité des medicaments biologiques dans le traitement du psoriasis.


Les études examinées comprennent des données sur les médicaments biologiques alefacept, efalizumab, etanercept et infliximab. Le présent article passe en revue l’ensemble des données publiées dans les périodiques spécialisés en dermatologie et listés sur la base MEDLINE, ainsi que les données présentées dans les résumés et sur les affiches des congrès de sociétés de dermatologues, notamment la réunion annuelle de la American Academy of Dermatology.


La majorité des études ont utilisé comme principale mesure d’efficacité une amélioration de 75 % de l’indice de surface et de sévérité du psoriasis (PASI 75).


En général, la biothérapie représente un ajout important au traitement du psoriasis; elle a une grande incidence sur le cours de la maladie et la qualité de vie de ceux qui en sont atteints.



Dr. Mamelak was funded by a grant from Connetics.


  1. 1.
    Koo, J. 1996Population-based epidemiologic study of psoriasis with emphasis on quality of life assessmentDermatol Clin14485496CrossRefPubMedGoogle Scholar
  2. 2.
    National Psoriasis Foundation. About psoriasis: FAQs [online article]. Available at:; accessed July 11, 2003
  3. 3.
    CDCP. Vital and health statistics: current estimates from the National Health Interview Survey, 1996. Centers for Disease Control and Prevention/National Center for Health Statistics. 2003Google Scholar
  4. 4.
    Krueger, G, Koo, J, Lebwohl, M,  et al. 2001The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership surveyArch Dermatol137280284PubMedGoogle Scholar
  5. 5.
    Barankin, B, DeKoven, J. 2001Psychosocial effect of common skin diseasesCan Fam48712716Google Scholar
  6. 6.
    Voorhees, JJ. 1996Dohi Memorial Lecture: Psoriasis—an immunological diseaseJ Dermatol23851857PubMedGoogle Scholar
  7. 7.
    Partsch, G, Steiner, G, Leeb, BF,  et al. 1997Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluidJ Rheumatol; 24518523Google Scholar
  8. 8.
    Danning, CL, Illei, GG, Hitchon, C,  et al. 2000Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritisArthritis Rheum4312441256CrossRefPubMedGoogle Scholar
  9. 9.
    Greaves, MW, Weinstein, GD. 1995Treatment of psoriasisN Engl J Med332581588CrossRefPubMedGoogle Scholar
  10. 10.
    Camisa, C. 2000Psoriasis: a clinical update on diagnosis and new therapiesCleve Clin J Med67105113, 117PubMedGoogle Scholar
  11. 11.
    Guenther, L. 2000Tazarotene combination treatments in psoriasisJ Am Acad Dermatol43S36S42CrossRefPubMedGoogle Scholar
  12. 12.
    Gordon, PM, Diffey, BL, Matthews, JN, Fair, PM. 1999A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasisJ Am Acad Dermatol41728732PubMedGoogle Scholar
  13. 13.
    Behrens, S, Grundmann–Kollmann, M, Schiener, R,  et al. 2000Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gelJ Am Acad Dermatol42493495CrossRefPubMedGoogle Scholar
  14. 14.
    Witman, PM. 2001Topical therapies for localized psoriasisMayo Clin Proc76943949PubMedGoogle Scholar
  15. 15.
    National Psoriasis Foundation. Benchmark survey on psoriasis and psoriatic arthritis. Available at:; accessed August 9, 2003
  16. 16.
    Tutrone, WD, Kagen, MH, Barbagallo, J,  et al. 2001Biologic therapy for psoriasis: a brief history, IICutis68367372PubMedGoogle Scholar
  17. 17.
    LaDuca, JR, Gaspari, AA. 2001Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseasesDermatol Clin19617635CrossRefPubMedGoogle Scholar
  18. 18.
    Food and Drug Administration. FDA approves first biologic therapy for psoriasis. Available at; accessed on November 5, 2003. FDA Talk Paper, 1-31-0003
  19. 19.
    Alefacept2003(Amevive) for treatment of psoriasisMed Lett Drugs Ther453132Google Scholar
  20. 20.
    Ortonne, JP. 2003Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasisJ Eur Acad Dermatol Verereol171216CrossRefGoogle Scholar
  21. 21.
    Lebwohl, M, Christophers, E, Langley, R,  et al. 2003An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasisArch Dermatol139719727CrossRefPubMedGoogle Scholar
  22. 22.
    Krueger, GG, Papp, KA, Stough, DB,  et al. 2002A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJ Am Acad Dermatol47821833CrossRefPubMedGoogle Scholar
  23. 23.
    Marzella L, Papadopoulos E, Wang C. PDA Final Clinical Review: Biologic License Application STN BL 125036/0 for alefacept for treatment of moderate to sever chronic plaque psoriasis, submitted April 29, 2002Google Scholar
  24. 24.
    Gottlieb AB, Blacker K, Duvic M, et al. Efficacy and safety of efalizumab long term treatment: preliminary findings from an open label trial [abstract]. Presented at the 61st Annual Spring 2003 Meeting of the American Academy of Dermatology, 21–26 March 2003, San Francisco, California, poster 11Google Scholar
  25. 25.
    Gottlieb AB, Gordon KB, Koo JY, et al. Long-term efalizumab treatment maintains clinical benefit in patients with moderate to severe plaque psoriasis: updated findings from an open-label trial [abstract]. Presented at the Annual Meeting of the American Academy of Dermatology, 25–29 July 2003, Chicago, Illinois, poster 43Google Scholar
  26. 26.
    Singri, P, West, DP, Gordon, KB. 2002Biologic therapy for psoriasis: the new therapeutic frontierArch Dermatol138657663CrossRefPubMedGoogle Scholar
  27. 27.
    PDA Advisory Committee. Genentech/Xoma Raptiva potential use as second-line psoriasis therapy to be discussed by committee [press release], September 8, 2003Google Scholar
  28. 28.
    Papadopoulos E, Marzella L. FDA Briefing Document: Biologic License Application STN BL 125075/0 for efalizumab for the treatment of moderate to severe chronic plaque psoriasis, submitted December 27, 2002Google Scholar
  29. 29.
    Gordon KB, Tyring SK, Hamilton TK, et al. Examining duration of response and rebound during treatment with efalizumab (anti-CD 11a) [abstract]. Presented at the 61st Annual Spring 2003 Meeting of the American Academy of Dermatology, 21–26 March 2003, San Francisco, California, poster 594Google Scholar
  30. 30.
    Mease, PJ, Goffe, BS, Metz, J,  et al. 2000Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialLancet356385390PubMedGoogle Scholar
  31. 31.
    Gottlieb AB, Lowe NJ, Matheson RT, et al. Efficacy of etanercept in patients with psoriasis [abstract]. Presented at the 60th Annual Spring 2003 Meeting of the American Academy of Dermatology, 22–27 February 2002, New Orleans, LouisianaGoogle Scholar
  32. 32.
    Papp K, Zitnik R. Efficacy and safety of etanercept in patients with psoriasis: results of a global 12 week phase III study [abstract]. Workshop presented at the 9th International Psoriasis Symposium, 17–22 June 2003, New York, New YorkGoogle Scholar
  33. 33.
    Leonardi C, Gottlieb AB, Zitnik R, for the Etanercept Psoriasis Study Group. Efficacy and safety of etanercept in patients with psoriasis: results of a phase 3 study [abstract]. Presented at the International Investigative Dermatology Annual Meetings, 30 April–4 May 2003, Miami Beach, Florida, poster 0409Google Scholar
  34. 34.
    Leonardi, CL, Powere, JL, Matheson, RT,  et al. 2003Etanercept as monotherapy in patients with psoriasisN Engl J Med34920142022CrossRefPubMedGoogle Scholar
  35. 35.
    Chaudhari, U, Romano, P, Mulcahy, LD,  et al. 2001Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trialLancet35718421847CrossRefPubMedGoogle Scholar
  36. 36.
    Gottlieb AB, Li S, Evans R, et al. Infliximab in the treatment of psoriasis: results from the first 10 weeks of the phase II trial [abstract]. Presented at the 61st Annual Spring 2003 Meeting of the American Academy of Dermatology, 21–26 March 2003, San Francisco, California, poster 596Google Scholar
  37. 37.
    Gottlieb AB, Evans R, Li S, et al. The efficacy and safety of infliximab induction therapy in patients with moderate to svere plaque-type psoriasis [abstract]. Poster presented at the 9th International Psoriasis Symposium, 17–22 June 2003, New York, New YorkGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2004

Authors and Affiliations

  1. 1.Department of DermatologyThe Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations